Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan Mak, Boazhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 3063–3064.

https://doi.org/10.1182/blood-2022-158570

Published: 2022

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff

Blood (2021) 138 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2021-148014

Published: 2021

Journal Articles

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Kyung Hee Chang, Tomasz Zal, Mahesh Basyal, Lauren Ostermann, Muharrem Muftuoglu, Po Yee Mak, Yannan Jia, Wenjing Tao, Malgorzata Anna Zal, William E. Fogler, John L. Magnani, Weiguo Zhang, Bing Z Carter, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2021-153661

Published: 2021

Journal Articles

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Bing Z Carter, Wenjing Tao, Lauren B Ostermann, Hong Mu-Mosley, Po Yee Mak, Steffen Boettcher, Yuki Nishida, Ran Tao, Eric Lang, Yifan Zhai, Dajun Yang, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3332.

https://doi.org/10.1182/blood-2021-148127

Published: 2021

Journal Articles

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Bing Z. Carter, Wenjing Tao, Po Yee Mak, Lauren B. Ostermann, Duncan Mak, Gerard McGeehan, Peter Ordentlich, Michael Andreeff

Blood (2021) 138 (17): 1637–1641.

https://doi.org/10.1182/blood.2021011917

Published: 2021

Includes: Supplemental data

Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141417

Published: 2020

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1267.

https://doi.org/10.1182/blood-2019-125725

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Bing Z Carter, PhD, Po Yee Mak, Steven M. Kornblau, MD, Wenjing Tao, Yuki Nishida, MD PhD, Vivian Ruvolo, MS, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1271.

https://doi.org/10.1182/blood-2019-124826

Published: 2019

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

Journal Articles

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Xiangmeng Wang, Po Yee Mak, Wencai Ma, Xiaoping Su, PhD, Hong Mu, MD PhD, Wenjing Tao, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2018) 132 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2018-99-118367

Published: 2018

Journal Articles

Novel ARC//IL1β/PGE2/β-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML

Bing Z Carter, PhD, Po Yee Mak, Xiangmeng Wang, PhD, Hong Mu, MD PhD, Wenjing Tao, PhD, Vivian Ruvolo, PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 3776.

https://doi.org/10.1182/blood.V130.Suppl_1.3776.3776

Published: 2017

Journal Articles

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

Xiangmeng Wang, PhD, Po Yee Mak, Hong Mu, MD PhD, Wenjing Tao, PhD, Jonathan A Pachter, PhD, David T Weaver, PhD, Bing Xu, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2017) 130 (Supplement 1): 2653.

https://doi.org/10.1182/blood.V130.Suppl_1.2653.2653

Published: 2017

Journal Articles

Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells

Wenjing Tao, PhD, Po Yee Mak, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2017) 130 (Supplement 1): 1586.

https://doi.org/10.1182/blood.V130.Suppl_1.1586.1586

Published: 2017

Journal Articles

Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML

Bing Z Carter, PhD, Po Yee Mak, Hong Mu, MD PhD, Duncan Mak, Ej Dettman, Michael Cardone, Xiangmeng Wang, PhD, Wendy Schober, Wenjing Tao, PhD, Takahiko Seki, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 4170.

https://doi.org/10.1182/blood.V130.Suppl_1.4170.4170

Published: 2017

Journal Articles

The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma

Bo Wang, MD, Liang Zhang, MD PhD, Lan Pham, PhD, Wenjing Tao, PhD, Hui Zhang, Jingmeng Xie, Wendy Chen, Qingqing Cai, MD PhD, Dehui Zou, MD PhD, Donglu Zhao, MD, Xiuhua Sun, MDPhD, Rong Liang, MD PhD, Jack Wang, Krystle Nomie, PhD, Nathan Fowler, MD, Michael Wang, MD

Blood (2015) 126 (23): 5126.

https://doi.org/10.1182/blood.V126.23.5126.5126

Published: 2015

NARROW

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Novel ARC//IL1β/PGE2/β-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells

Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML

The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only